Literature DB >> 24285177

HLA-DPB1 and anti-HBs titer kinetics in hepatitis B booster recipients who completed primary hepatitis B vaccination during infancy.

T-W Wu1, C-C Chu2, H-W Chang Liao3, S-K Lin3, T-Y Ho3, M Lin4, H H Lin5, L-Y Wang6.   

Abstract

Previously we reported significant associations of the human leukocyte antigen (HLA)-DPB1 05:01 with memory against hepatitis B (HB) vaccination. However, the effects of HLA-DPB1 on antibodies to hepatitis B surface antigen (anti-HBs) kinetics were not explored. We followed up a cohort of 1974 HB booster recipients and quantified their 1-month and 1-year post-booster anti-HBs titers. A total of 681 subjects were randomly selected and typed for HLA-DPB1. We found that male subjects, undetectable pre-booster titers, and 05:01 homozygotes led to significantly lower post-booster anti-HBs titers. The geometric means (95% confidence interval (CI)) of 1-month post-booster anti-HBs titers were 4.68 (2.69-8.12), 23.01 (14.96-35.40) and 50.06 (27.20-92.13) mIU ml(-1) for subjects carrying two, one and no HLA-DPB1 05:01 allele. The corresponding figures for 1-year post-booster anti-HBs titers were 1.26 (0.73-2.18), 4.72 (3.08-7.25) and 7.32 (3.75-13.56) mIU ml(-1). There were significant associations of post-booster anti-HBs titers with the number of HLA-DPB1 risk and protective alleles. Among booster responders, anti-HBs decay rates were significantly reduced in subjects who had detectable pre-booster anti-HBs titers and the HLA-DPB1 05:01 allele. Our results indicated that HLA-DPB1 influences the kinetics of anti-HBs. The long-term memory against hepatitis B surface antigen (HBsAg) and the residual serum titers of anti-HBs after HB vaccination may be influenced by different mechanisms as evidenced by their inverse trend of associations with the 05:01 allele.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24285177     DOI: 10.1038/gene.2013.62

Source DB:  PubMed          Journal:  Genes Immun        ISSN: 1466-4879            Impact factor:   2.676


  54 in total

1.  A gender gap in autoimmunity.

Authors:  C C Whitacre; S C Reingold; P A O'Looney
Journal:  Science       Date:  1999-02-26       Impact factor: 47.728

2.  Plasma cells for a lifetime?

Authors:  Rudolf A Manz; Andreas Radbruch
Journal:  Eur J Immunol       Date:  2002-04       Impact factor: 5.532

3.  Correlation analysis between frequencies of circulating antigen-specific IgG-bearing memory B cells and serum titers of antigen-specific IgG.

Authors:  H Leyendeckers; M Odendahl; A Löhndorf; J Irsch; M Spangfort; S Miltenyi; N Hunzelmann; M Assenmacher; A Radbruch; J Schmitz
Journal:  Eur J Immunol       Date:  1999-04       Impact factor: 5.532

4.  Estrogen influences the differentiation, proliferation, and survival of early B-lineage precursors.

Authors:  K L Medina; A Strasser; P W Kincade
Journal:  Blood       Date:  2000-03-15       Impact factor: 22.113

5.  Duration of humoral immunity to common viral and vaccine antigens.

Authors:  Ian J Amanna; Nichole E Carlson; Mark K Slifka
Journal:  N Engl J Med       Date:  2007-11-08       Impact factor: 91.245

6.  A biological role for the major histocompatibility antigens.

Authors:  P C Doherty; R M Zinkernagel
Journal:  Lancet       Date:  1975-06-28       Impact factor: 79.321

7.  Estrogen alters thresholds for B cell apoptosis and activation.

Authors:  Christine M Grimaldi; James Cleary; A Selma Dagtas; Dariush Moussai; Betty Diamond
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

8.  Hepatitis B: the virus and disease.

Authors:  T Jake Liang
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

9.  High non-responsiveness of males and the elderly to standard hepatitis B vaccination among a large cohort of healthy employees.

Authors:  Angelique P A Vermeiren; Christian J P A Hoebe; Nicole H T M Dukers-Muijrers
Journal:  J Clin Virol       Date:  2013-07-26       Impact factor: 3.168

10.  APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells.

Authors:  Elodie Belnoue; Maria Pihlgren; Tracy L McGaha; Chantal Tougne; Anne-Françoise Rochat; Claudia Bossen; Pascal Schneider; Bertrand Huard; Paul-Henri Lambert; Claire-Anne Siegrist
Journal:  Blood       Date:  2008-01-07       Impact factor: 22.113

View more
  4 in total

1.  HLA-DPB1 and HLA class I confer risk of and protection from narcolepsy.

Authors:  Hanna M Ollila; Jean-Marie Ravel; Fang Han; Juliette Faraco; Ling Lin; Xiuwen Zheng; Giuseppe Plazzi; Yves Dauvilliers; Fabio Pizza; Seung-Chul Hong; Poul Jennum; Stine Knudsen; Birgitte R Kornum; Xiao Song Dong; Han Yan; Heeseung Hong; Cristin Coquillard; Joshua Mahlios; Otto Jolanki; Mali Einen; Isabelle Arnulf; Sophie Lavault; Birgit Högl; Birgit Frauscher; Catherine Crowe; Markku Partinen; Yu Shu Huang; Patrice Bourgin; Outi Vaarala; Alex Désautels; Jacques Montplaisir; Steven J Mack; Michael Mindrinos; Marcelo Fernandez-Vina; Emmanuel Mignot
Journal:  Am J Hum Genet       Date:  2015-01-08       Impact factor: 11.025

2.  RTS,S malaria vaccine efficacy and immunogenicity during Plasmodium falciparum challenge is associated with HLA genotype.

Authors:  C M Nielsen; J Vekemans; M Lievens; K E Kester; J A Regules; C F Ockenhouse
Journal:  Vaccine       Date:  2018-02-10       Impact factor: 3.641

3.  Association of HLA-DPA1, HLA-DPB1, and HLA-DQB1 Alleles With the Long-Term and Booster Immune Responses of Young Adults Vaccinated Against the Hepatitis B Virus as Neonates.

Authors:  Wen-Chang Wang; Yu-Shiang Lin; Yin-Fan Chang; Chih-Ching Yeh; Chien-Tien Su; Jin-Shang Wu; Fu-Hsiung Su
Journal:  Front Immunol       Date:  2021-08-18       Impact factor: 7.561

4.  Genetic variants in human leukocyte antigen-DP influence both hepatitis C virus persistence and hepatitis C virus F protein generation in the Chinese Han population.

Authors:  Xiaodong Xu; Ming Yue; Longfeng Jiang; Xiaozhao Deng; Yongxiang Zhang; Yun Zhang; Danyan Zhu; Wen Xiao; Zhenxian Zhou; Wenjuan Yao; Jing Kong; Xiaojie Yu; Juan Wei
Journal:  Int J Mol Sci       Date:  2014-06-03       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.